Cardiovascular and Metabolic
Corticotropin-releasing factor type 2 receptor signalling
Selective activation of CRF2 receptors by urocortin-II and urocortin-III.
Biological pathway
CRF2 receptor activation increases cyclic AMP and can produce vasodilation, altered cardiac output, neurohormonal effects and tissue-specific metabolic responses.
Evidence summary
Human infusion studies show potent vasodilation and haemodynamic activity; heart-failure studies remain exploratory.
Limitations
Small samples, short infusions and haemodynamic surrogate outcomes limit conclusions about clinical efficacy and safety.